Compare Neurocrine Biosciences Inc (NBIX) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Invesco Preferred ETF — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Invesco Preferred ETF trades at $10.04 (market cap $3.64B). The key difference: Neurocrine Biosciences Inc is far larger — about 4× Invesco Preferred ETF's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Invesco Preferred ETF for 94 Days on average.
| NBIX | PGX | |
|---|---|---|
Market Cap | $14.60B | $3.64B |
Volume | 1,075,694 | 6,969,114 |
Sector | Health | — |
52-Week High | $185.50 | $11.61 |
52-Week Low | $123.10 | $9.97 |
Typical Hold Time | 23 Days | 94 Days |
Enterprise Value | $14.61B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
PGX trades at $9.97, down 0.89% with a bearish technical signal from moving averages despite oversold RSI readings. The stock shows identical support and resistance at $10, indicating consolidation. Recent dividend payments of $0.06 were declared for July and September 2026, providing income appeal. Financial ratios including P/E, P/S, and ROE are unavailable in current data, limiting fundamental visibility.
The outlook remains cautious due to bearish technical momentum and lack of current financial metrics. Income investors may find dividend payments attractive, but absence of earnings data and weak price action suggest near-term pressure. Key risks include undefined profitability and competitive challenges in the preferred ETF space highlighted by recent media coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
